- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Frankfurt | 96,260 | 26.07.24 21:23:45 | -0,460 | -0,48% | 0,000 | 0,000 | 96,200 | 96,260 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 997,000 | 26.07.24 18:24:32 | +21,000 | +2,15% | 0,000 | 0,000 | 978,000 | 997,000 |
